Hydromorphone Quintian 2 Mg/Ml (Hydromorphone Hydrochloride)

Hydromorphone, an opioid analgesic acting on the µ‑opioid receptor pathway, is indicated for the following clinical situations:

• Moderate to severe acute pain: provides rapid, potent analgesia for short‑term severe pain episodes in adult patients.
• Post‑operative pain: manages pain following surgical procedures, facilitating recovery and patient comfort.
• Cancer‑related pain: controls persistent pain associated with malignant disease, improving quality of life.

• Hydromorphone binds with high affinity to µ‑opioid receptors in the central nervous system, activating G‑protein coupled pathways that inhibit adenylate cyclase activity. This reduces neuronal excitability and decreases the release of nociceptive neurotransmitters such as substance P and glutamate, resulting in strong analgesic and sedative effects.

Hydromorphone may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Nausea: feeling of sickness or urge to vomit.
• Constipation: reduced bowel movements and hard stools.
• Drowsiness: increased sleepiness or fatigue.
• Dizziness: sensation of light‑headedness or unsteadiness.
• Vomiting: expulsion of stomach contents.
• Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure causing dizziness or fainting.
• Anaphylactic reaction: sudden, severe allergic response with rash, swelling, or airway compromise.
• Adrenal insufficiency: inadequate cortisol production leading to fatigue and low blood pressure.
• Seizures: uncontrolled electrical activity in the brain.
• Dependence or addiction: compulsive use despite harmful consequences.

When using Hydromorphone, clinicians should observe the following precautions to minimize risks.

• Assess respiratory function: evaluate baseline breathing and monitor for depression during therapy.
• Monitor sedation level: watch for excessive drowsiness or loss of consciousness.
• Adjust dose in renal or hepatic impairment: reduce dosage or increase interval in patients with organ dysfunction.
• Avoid concurrent CNS depressants: limit use with benzodiazepines, barbiturates, or alcohol.
• Use cautiously in elderly patients: start with lower doses and titrate slowly.
• Store at controlled room temperature: keep in original container, protect from moisture and light.

Hydromorphone can interact with other medicines; notable interactions are categorized by clinical significance.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use can precipitate severe hypertension or serotonin syndrome.
• Other opioids: combined use increases risk of respiratory depression and profound sedation.
• Benzodiazepines: additive central nervous system depression may be life‑threatening.
• Alcohol: enhances sedative effects and respiratory compromise.
• CNS depressants: concurrent use with antihistamines or muscle relaxants may cause excessive sedation.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase hydromorphone plasma levels.
• CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect.
• Selective serotonin reuptake inhibitors: risk of serotonin syndrome, monitor patient.
• Anticholinergic agents: may worsen constipation.
• Diuretics: may potentiate hypotensive effects.